Incidence of malignancy after living kidney transplantation: A multicen-ter study from Iran
View/ Open
Date
2012Author
Einollahi, B
Rostami, Z
Nourbala, MH
Lessan-Pezeshki, M
Sim-foroosh, N
Nemati, E
Pourfarziani, V
Beiraghdar, F
Nafar, M
Pour-Reza-Gholi, F
Mazdeh, MM
Amini, M
Ahmadpour, P
Makhdoomi, K
Ghafari, A
Ardalan, MR
Khosroshahi, HT
Oliaei, F
Shahidi, S
Abbaszadeh, S
Fatahi, MR
Hiedari, F
Makhlogh, A
Azmandian, J
Samimagham, HR
Shahbazian, H
Nazemian, F
Naghibi, M
Khosravi, M
Monfared, A
Mosavi, SM
Ahmadi, J
Jalalzadeh, M
Metadata
Show full item recordAbstract
Malignancy is a common complication after renal transplantation. However, limited data are available on post-transplant malignancy in living kidney transplantation. Therefore, we made a plan to evaluate the incidence and types of malignancies, association with the main risk factors and patient survival in a large population of living kidney transplantation. We conducted a large retrospective multicenter study on 12525 renal recipients, accounting for up to 59% of all kidney transplantation in Iran during 22 years follow up period. All information was collected from observation of individual notes or computerized records for transplant patients. Two hundred and sixty-six biopsy-proven malignancies were collected from 16 Transplant Centers in Iran; 26 different type of malignancy categorized in 5 groups were detected. The mean age of patients was 46.2آ±12.9 years, mean age at tumor diagnosis was 50.8آ±13.2 years and average time between transplantation and detection of malignancy was 50.0آ±48.4 months. Overall tumor incidence in recipients was 2%. Kaposis' sarcoma was the most common type of tumor. The overall mean survival time was 117.1 months (95% CI: 104.9-129.3). In multivariate analysis, the only independent risk factor associated with mortality was type of malignancy. This study revealed the lowest malignancy incidence in living unrelated kidney transplantation. آ© Ivyspring International Publisher.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Exosomes in cancer: small vesicular transporters for cancer progression and metastasis, biomarkers in cancer therapeutics
Abak, A; Abhari, A; Rahimzadeh, S (2018)Cancer progression is a polygenic procedure in which the exosomes can function as substantial roles. Exosomes are tiny, phospholipid bilayer membrane nanovesicles of endocytic derivation with a diameter of 40-100 nm. These ... -
Investigating the effect of trimethyl-chitosan-hyaluronate nanoparticles loaded with anti-STAT-3 and anti-Tim-3 siRNA molecules in 4T1 (breast cancer) and CT26 (colorectal cancer) cancer cells
Karami, Reza (Tabriz University of Medical Sciences, Faculty of Medicine, 2024)Tim-3 has been introduced as an important checkpoint in the immune system in recent years and is known as an immune suppressive factor in the tumor microenvironment. STAT-3 has also been introduced as one of the important ... -
Anti?inflammatory and anti?tumor effects of ?-L-guluronic acid (G2013) on cancer-related inflammation in a murine breast cancer model
Hosseini, F; Mahdian-Shakib, A; Jadidi-Niaragh, F; Enderami, SE; Mohammadi, H; Hemmatzadeh, M; Mohammed, HA; Anissian, A; Kokhaei, P; Mirshafiey, A; Hassannia, H (2018)Cancer-related inflammation (CRI) is associated with the malignant progression of several cancer types. Targeting these pathways is a novel promising strategy for cancer prevention and treatment. In this present study, we ...